Disc Medicine(IRON)

Search documents
Disc Medicine Presents Positive Data from SAD Cohorts of a Phase 1b Trial in Patients with Chronic Kidney Disease (CKD) and Anemia at the 2024 American Society of Nephrology (ASN) Kidney Week
GlobeNewswire News Room· 2024-10-25 17:00
WATERTOWN, Mass., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today presented positive additional data from an ongoing Phase 1b study of DISC-0974 in patients with non-dialysis-dependent chronic kidney disease (NDD-CKD) and anemia, including results from the 40 mg and 60 mg single ascending dose (SAD) co ...
Disc Medicine Announces Presentation of New Data from Phase 1b Trial of DISC-0974 in Patients with Chronic Kidney Disease (CKD) and Anemia at 2024 American Society of Nephrology (ASN) Kidney Week
GlobeNewswire News Room· 2024-10-11 12:00
Core Insights - Disc Medicine, Inc. is set to present clinical data on DISC-0974 at the 2024 ASN Kidney Week, focusing on its Phase 1b study in patients with non-dialysis dependent chronic kidney disease and anemia [1][2] - The study aims to evaluate safety and changes in hepcidin, iron levels, and hematologic parameters [1][2] Presentation Details - The presentation will include data from the 40mg and 60mg dose cohorts, covering safety, pharmacokinetics, and effects on hepcidin and anemia [2][3] - The abstract for the presentation is available on the ASN Kidney Week conference website [2] Company Overview - Disc Medicine is a clinical-stage biopharmaceutical company dedicated to developing novel treatments for serious hematologic diseases, focusing on red blood cell biology and iron homeostasis [4]
Disc Medicine to Participate in Upcoming Investor Conferences
GlobeNewswire News Room· 2024-08-30 12:00
WATERTOWN, Mass., Aug. 30, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that company management will participate in fireside chats at four upcoming investor conferences: 2024 Wells Fargo Securities Healthcare Conference on Friday, September 6th at 10:15 a.m. ET. Morgan Stanley 22nd Annual Global He ...
LEADING FINTECH MONEYTHUMB ACQUIRED BY IRON CREEK
Prnewswire· 2024-08-29 11:01
Partnership to Accelerate Future Growth and Innovation of MoneyThumb's SaaS Document Evaluation Technology SAN DIEGO, Aug. 29, 2024 /PRNewswire/ -- MoneyThumb, a leader in automated document evaluation and fraud detection solutions announced today that it has been acquired by Iron Creek Partners LLC ("Iron Creek"), a private investment firm with a focus on investments in the software, data, communications, and business services industries. Iron Creek led the investment group, which also included Main Street ...
Disc Medicine Announces Underwritten Offering of Common Stock
Newsfilter· 2024-06-14 12:03
The securities described above are being offered by Disc pursuant to a shelf registration statement on Form S-3 (No. 333-275652) that was declared effective by the Securities and Exchange Commission (SEC) on November 29, 2023. This offering is being made only by means of a prospectus and prospectus supplement that form a part of the registration statement. A prospectus supplement and accompanying prospectus related to the offering will be filed with the SEC and will be available on the SEC's website at www. ...
Disc Medicine Announces Underwritten Offering of Common Stock
GlobeNewswire News Room· 2024-06-14 12:03
Cautionary Statement Regarding Forward-Looking Statements Disc intends to use the net proceeds from the offering to fund research and clinical development of its current or additional product candidates, as well as for working capital and other general corporate purposes. WATERTOWN, Mass., June 14, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients sufferin ...
Disc Medicine Presents Positive Clinical Data Across Portfolio at the European Hematology Association (EHA) 2024 Congress
GlobeNewswire News Room· 2024-06-14 11:30
WATERTOWN, Mass., June 14, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced positive additional data for bitopertin in erythropoietic protoporphyria (EPP), including additional analyses of AURORA data that further demonstrated the clinical activity of bitopertin and highlighted meaningful improvements ...
Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2024 Congress
Newsfilter· 2024-05-14 14:30
WATERTOWN, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced that it will present data from multiple programs in its hematology portfolio at the upcoming European Hematology Association (EHA) 2024 Congress, which will be held in Madrid Spain on June 13-16, 2024. "We are excited to share f ...
Disc Medicine(IRON) - 2024 Q1 - Quarterly Report
2024-05-09 12:15
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________________ to __________________ Commission File Number: 001-39438 Disc Medicine, Inc. (Exact name of registrant as specified in its charter) Delaware 85-1612845 ...
Disc Medicine(IRON) - 2024 Q1 - Quarterly Results
2024-05-09 12:07
Exhibit 99.1 Disc Medicine Reports First Quarter 2024 Financial Results and Provides Business Update WATERTOWN, Mass. (May 9, 2024) – Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today reported financial results for the first quarter ended March 31, 2024. "The topline data from AURORA, presented in April, strengthened our belief that bito ...